SCHEMBL1574593

SCHEMBL1574593

CCOc1ccccc1NC(=O)N1CC(N(CC)c2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
BLM P54132 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GAA P10253 1/20 0.48
HSD17B10 Q99714 2/20 0.48
POLB P06746 3/20 0.47
MAPT P10636 2/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 2/20 0.47
GLA P06280 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574613 0.91 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2BLMMEN1KMT2A
SCHEMBL1574948 0.88 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2BLMMEN1KMT2A
SCHEMBL1574582 0.86 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2BLMMEN1KMT2A
SCHEMBL1574868 0.85 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2BLMMEN1KMT2A
SCHEMBL1574875 0.84 GAA (0.47) SMN1; SMN2KMT2AGAALMNA
SCHEMBL1574665 0.84 TAAR1 (0.50) ALDH1A1MEN1KMT2AGAAMAPT
SCHEMBL1575172 0.83 KDM4E (0.58) SMN1; SMN2KMT2AGAAMAPTCYP2C19
SCHEMBL1574890 0.83 GAA (0.51) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
SCHEMBL1574978 0.82 KMT2A (0.60) ALDH1A1SMN1; SMN2KMT2AGAAHSD17B10
SCHEMBL1574472 0.82 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2BLMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-B1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO (JP) 2015-02-25 EP disclosed
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB ALDH1A1 1445/4885SMN1; SMN2 1838/4885BLM 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.